#1 Clinical Trials Search in Europe

Doxorubicin

Doxorubicin, also known by brand names like Doxil and Caelyx, is an important chemotherapy drug being studied in various clinical trials for treating different types of cancer. This article explores how doxorubicin, particularly in its liposomal formulations, is being investigated to improve cancer treatment outcomes while managing side effects.

Table of Contents

What is Doxorubicin?

Doxorubicin is a powerful chemotherapy drug used to treat various types of cancer. It belongs to a class of medications called anthracyclines. Doxorubicin is also known by several other names, including:

  • Adriamycin
  • Doxorubicin hydrochloride
  • Liposomal doxorubicin hydrochloride
These different names may refer to slightly different formulations of the drug, but they all contain the same active ingredient[1].

How Doxorubicin Works

Doxorubicin works by interfering with the DNA in cancer cells. This interference prevents the cancer cells from dividing and growing, ultimately leading to their death. By targeting rapidly dividing cells, doxorubicin can effectively slow down or stop the growth of tumors[2].

Conditions Treated with Doxorubicin

Doxorubicin is used to treat a wide range of cancers, including:

  • Breast cancer: It is commonly used in combination with other drugs for both early-stage and advanced breast cancer[3].
  • Ovarian cancer: Doxorubicin, especially in its liposomal form, is used to treat advanced ovarian cancer[1].
  • Soft tissue sarcomas: These are rare cancers that develop in soft tissues like muscles and fat[4].
  • Multiple myeloma: A type of blood cancer affecting plasma cells[5].
  • Endometrial cancer: Cancer of the lining of the uterus[2].
  • Acute lymphoblastic leukemia: A type of blood cancer affecting white blood cells[6].

How Doxorubicin is Administered

Doxorubicin is typically given as an intravenous (IV) infusion, which means it’s delivered directly into your bloodstream through a vein. The dosage and frequency of treatment can vary depending on the specific condition being treated and other factors. Some common administration methods include:

  • A single dose every 21 days[3]
  • Weekly doses for several weeks[7]
  • Continuous infusion over 96 hours[6]
Your doctor will determine the best dosing schedule for your specific situation.

Side Effects and Risks

Like all chemotherapy drugs, doxorubicin can cause side effects. Some of the most important ones to be aware of include:

  • Heart problems: Doxorubicin can potentially damage the heart, especially at high cumulative doses. Your doctor will monitor your heart function closely during treatment[8].
  • Bone marrow suppression: This can lead to a decrease in blood cell counts, increasing the risk of infection, anemia, and bleeding[5].
  • Hand-foot syndrome: Also known as palmar-plantar erythrodysesthesia (PPE), this condition causes redness, swelling, and pain in the palms of the hands and soles of the feet[8].
  • Nausea and vomiting
  • Hair loss
Your healthcare team will work with you to manage these side effects and may adjust your treatment if necessary.

New Formulations of Doxorubicin

Researchers are continually working on developing new formulations of doxorubicin to improve its effectiveness and reduce side effects. Some of these include:

  • Liposomal doxorubicin: This formulation encases the drug in tiny fat bubbles called liposomes. Brand names include Doxil, Caelyx, and Myocet. Liposomal doxorubicin may reduce the risk of heart problems and other side effects[8].
  • TLD-1 (Talidox): A new liposomal formulation designed to potentially reduce the risk of hand-foot syndrome while maintaining the drug’s effectiveness[8].

Ongoing Research and Clinical Trials

Numerous clinical trials are underway to further improve the use of doxorubicin in cancer treatment. Some areas of research include:

  • Combining doxorubicin with other drugs to enhance its effectiveness[4].
  • Using doxorubicin before surgery (neoadjuvant therapy) to shrink tumors[7].
  • Developing new formulations to reduce side effects[8].
  • Exploring the use of doxorubicin in different types of cancer and at various stages of disease.
These ongoing studies aim to optimize the use of doxorubicin and improve outcomes for cancer patients.

Aspect Details
Drug Formulations Standard doxorubicin, pegylated liposomal doxorubicin (Doxil/Caelyx), novel liposomal formulations (e.g. TLD-1)
Cancer Types Studied Acute lymphoblastic leukemia, ovarian cancer, breast cancer, glioblastoma, multiple myeloma
Common Dosing Schedules Every 2-4 weeks or weekly, specific doses vary by trial and formulation
Combination Therapies Often combined with other chemotherapy drugs (e.g. cyclophosphamide, vincristine) or targeted therapies (e.g. bortezomib)
Key Endpoints Efficacy (tumor response, survival), safety/tolerability, pharmacokinetics, bioequivalence of formulations
Potential Advantages Improved tumor targeting, reduced cardiotoxicity, potentially fewer side effects like alopecia
Monitored Side Effects Hematological toxicity, cardiac function, hand-foot syndrome, nausea, fatigue

FAQ

  • What is doxorubicin and how does it work? Doxorubicin is an anthracycline chemotherapy drug that works by damaging cancer cell DNA and preventing the cells from dividing and growing. It is often used in liposomal formulations (enclosed in tiny fat particles) to improve its delivery to tumor sites and reduce side effects.
  • What types of cancer is doxorubicin being studied for? Clinical trials are investigating doxorubicin for various cancers including acute lymphoblastic leukemia, ovarian cancer, breast cancer, glioblastoma (brain cancer), and multiple myeloma. It is being studied both as a single agent and in combination with other drugs.
  • What are some potential advantages of liposomal doxorubicin formulations? Liposomal formulations like Doxil/Caelyx may offer benefits such as improved delivery to tumor sites, reduced cardiotoxicity compared to standard doxorubicin, and potentially fewer side effects like hair loss. Some trials are comparing different liposomal formulations to optimize these advantages.
  • How is doxorubicin typically administered in clinical trials? Doxorubicin is usually given as an intravenous infusion, with dosing schedules varying by trial. Common regimens include administration every 2-4 weeks or weekly dosing. The exact dose and schedule depend on the specific trial protocol and cancer type being treated.
  • What are some side effects being monitored in doxorubicin trials? While liposomal formulations aim to reduce side effects, trials still closely monitor for potential adverse events. These may include lowered blood cell counts, nausea, fatigue, and skin reactions like hand-foot syndrome. Cardiac function is also carefully evaluated due to potential heart-related side effects.

Ongoing Clinical Trials on Doxorubicin

  • Study of ribociclib with or without chemotherapy for patients with hormone receptor positive, HER2 negative early breast cancer at intermediate risk

    Recruiting

    1 1 1 1
    Investigated drugs:
    France Germany Italy The Netherlands Spain

  • Study of pembrolizumab with drug combination for first-line treatment in patients with advanced-stage classic Hodgkin lymphoma

    Recruiting

    1 1 1
    Investigated drugs:
    Germany

  • Study of Blinatumomab and a drug combination for older adults with newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphoblastic Leukemia

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Bulgaria Czechia Denmark Estonia +11

  • A Study of Puxitatug Samrotecan Compared to Chemotherapy for Patients with Advanced Endometrial Cancer After Previous Platinum and Immunotherapy Treatment

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +9

  • Study evaluating HER2DX-guided treatment in patients with early-stage HER2-positive breast cancer using trastuzumab, pertuzumab and combination chemotherapy

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Ireland Spain

  • Study on Dinutuximab Beta and Drug Combination for Children, Teens, and Adults with GD2-Positive Ewing Sarcoma

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Czechia Germany Sweden

  • Study of olaparib and chemotherapy combination in stage III breast cancer patients with HER2-negative, hormone receptor impaired or deficient disease

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France The Netherlands

  • Study on the Effectiveness and Safety of Belinostat and Pralatrexate with Drug Combination for Newly Diagnosed Peripheral T-Cell Lymphoma Patients

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Hungary Italy Poland Spain

  • Study of drug combinations including irinotecan, ifosfamide, vincristine, dactinomycin, regorafenib and other agents for children and adults with rhabdomyosarcoma

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +10

  • Study of Dostarlimab for Patients with Advanced or Metastatic Non-Colorectal/Non-Endometrial Cancer with dMMR/MSI, Compared to Standard Drug Combination

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Anthracycline: A class of chemotherapy drugs, including doxorubicin, that work by damaging cancer cell DNA and preventing cell division.
  • Liposomal: A drug delivery method where the medication is enclosed in tiny fat particles (liposomes) to improve its distribution in the body and potentially reduce side effects.
  • Pegylated: A process of attaching polyethylene glycol (PEG) molecules to a drug to improve its stability and circulation time in the body.
  • Cardiotoxicity: Damage to the heart muscle that can occur as a side effect of some cancer treatments, including standard doxorubicin.
  • Hand-foot syndrome: A skin reaction that can occur with some chemotherapy drugs, causing redness, swelling, and pain in the palms of the hands and soles of the feet.
  • Bioequivalence: When two medications have the same active ingredient and produce the same effects in the body, despite potentially being manufactured differently.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Dose-limiting toxicity: Side effects that are severe enough to prevent increasing the dose of a drug in a clinical trial.
  • Progression-free survival: The length of time during and after treatment that a patient lives without their cancer getting worse.
  • RECIST criteria: Response Evaluation Criteria in Solid Tumors – a standard way to measure how well a cancer patient responds to treatment in clinical trials.

References

  1. https://clinicaltrials.gov/study/NCT01715168
  2. https://clinicaltrials.gov/study/NCT00002493
  3. https://clinicaltrials.gov/study/NCT00002707
  4. https://clinicaltrials.gov/study/NCT04032964
  5. https://clinicaltrials.gov/study/NCT00002878
  6. https://clinicaltrials.gov/study/NCT00600977
  7. https://clinicaltrials.gov/study/NCT00542191
  8. https://clinicaltrials.gov/study/NCT03387917